Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein Academic Article uri icon

Overview

MeSH Major

  • C-Reactive Protein
  • Cardiovascular Diseases
  • Fluorobenzenes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrimidines
  • Sulfonamides

abstract

  • In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.)

publication date

  • November 20, 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa0807646

PubMed ID

  • 18997196

Additional Document Info

start page

  • 2195

end page

  • 207

volume

  • 359

number

  • 21